<DOC>
	<DOCNO>NCT00416507</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , fluorouracil , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving one drug ( combination chemotherapy ) together radiation therapy may kill tumor cell . It yet know treatment regimen effective pancreatic cancer . PURPOSE : This randomized phase III trial study gemcitabine , fluorouracil , cisplatin , radiation therapy see well work compare gemcitabine alone treat patient nonmetastatic pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine With Without Combination Chemotherapy Radiation Therapy Treating Patients With Nonmetastatic Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient nonresectable , nonmetastatic adenocarcinoma pancreas treat gemcitabine hydrochloride v without fluorouracil , cisplatin , radiotherapy follow gemcitabine hydrochloride . Secondary - Compare toxicity regimens patient . - Compare objective response ( complete , partial , stable ) patient treat regimen . - Compare clinical benefit , term general condition weight maintenance patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord WHO performance status ( 0 1 v 2 ) , initial treatment ( laparotomy without bilio-digestive diversion ) ( yes v ) , peritoneal cytology ( positive v negative ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV 15 minute day 1-5 29-33 fluorouracil IV continuously day 1-40 . Patients also undergo radiotherapy daily , 5 day week , 6 week . - Arm II : Patients receive gemcitabine hydrochloride IV 15 minute day 1 . Treatment repeat every 7 day 7 week . Beginning week 11 arm I week 9 arm II , patient receive gemcitabine hydrochloride IV 15 minute day 1 , 8 , 15 . Treatment repeat every 4 week 10 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 190 patient accrue trial .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas No neuroendocrine histologies No extraabdominal metastases No hepatic peritoneal metastasis celioscopy Peritoneal carcinomatous ( cytology positive peritoneal lavage ) may allow Nonresectable disease meeting ≥ 1 follow criterion : Arterial invasion Mesentericportal vein invasion &gt; 15 mm less hemicircumference Satellite adenopathy encompass radiation field PATIENT CHARACTERISTICS : WHO performance status 02 Bilirubin &lt; 1.75 mg/dL Creatinine &lt; 1.5 mg/dL WBC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ No major organ disorder , include cardiac coronary insufficiency Prothrombin time &gt; 80 % No psychiatric social condition would preclude study therapy No malignancy except nonmelanoma skin cancer carcinoma situ cervix No contraindication radiotherapy chemotherapy No intractable pancreatic pain relieve morphine and/or analgesic radiotherapy PRIOR CONCURRENT THERAPY : No prior adjuvant palliative chemotherapy radiotherapy Prior surgical diversion biliary and/or digestive tract allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>